ʻO ka hōʻike mua o nā ʻike mai ka hoʻokolohua lapaʻau NCT02735707 i hōʻike ʻia ma ka preprint e hōʻike ana he kūpono ʻo Tocilizumab lāua ʻo Sarilumab, nā antagonists receptor interleukin-6, i ka mālama ʻana i nā maʻi maʻi COVID-19 koʻikoʻi a hoʻomaikaʻi i ke ola.
Ua pane maikaʻi nā maʻi COVID-19 maʻi nui i loaʻa ke kākoʻo mālama koʻikoʻi i ka mālama ʻana me nā antagonists receptor IL-6, tocilizumab a me sarilumab. ʻO ka make ma ka haukapila he 28.0% no tocilizumab, 22.2% no sarilumab a me 35.8% no ka mana hoʻomalu ʻo ia hoʻi ua hoʻomaikaʻi ʻia ka nui o ke ola e kākoʻo ana i ka pono maikaʻi o kēia mau lāʻau i hoʻohana hou ʻia. (1)
ʻO nā lāʻau lapaʻau tocilizumab (kahi antibody monoclonal humanized e kūʻē i ka receptor IL-6) a me sarilumab (kahi antibody monoclonal kanaka e kūʻē i ka receptor IL-6) e hoʻohana maʻamau ʻia e like me nā immunosuppressants i ka mālama ʻana i ka rheumatoid arthritis.
I ke aniau o kēia wā o ka maʻi ahulau COVID-19 i ka wā e kiʻekiʻe ai ka nui o ka make a me ka maʻi, he mea hoihoi loa ia e hoʻomaopopo ua hōʻemi nui kēia mau lāʻau lapaʻau ʻelua i hoʻohana hou ʻia i ka noho ʻana o nā maʻi COVID-19 ma nā keʻena mālama koʻikoʻi o ka haukapila a ua hōʻemi i ka nui o ka make ma kahi o ka hapaha. ʻO ke ʻano o kēia, ʻo ia hoʻi ka emi ʻana o nā make a me ka noho pōkole ʻana ma ka mālama koʻikoʻi, no laila e mālama ana i ka hiki i nā haukapila ke lawelawe i ka maʻi ahulau.
Ua kākoʻo ʻia kēia hoʻokolohua lapaʻau e ka EU e kākoʻo ana iā REMAP-CAP ma o ka papahana Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE). Loaʻa ke kākoʻo hou aku mai ka papahana Rapid European SARS-CoV-2 Emergency Research response (RECOVER) e pili ana (2).
***
Sources:
- Nā mea noiʻi REMAP-CAP, Gordon AC., 2020. Interleukin-6 Receptor Antagonists i nā maʻi Critically Ill me Covid-19 - Hōʻike mua. Paʻi mua: MedRxiv. Posted January 07, 2021. DOI: https://doi.org/10.1101/2021.01.07.21249390
- Komisina ʻEulopa, 2021. Nūhou - Ua loaʻa i ka hoʻokolohua lapaʻau kālā kālā ʻo EU i nā lāʻau lapaʻau hou e kūpono i ka COVID-19. Paʻi ʻia 8 Ianuali 2021. Loaʻa ma ka pūnaewele https://ec.europa.eu/info/news/eu-funded-clinical-trial-finds-new-treatments-be-effective-against-covid-19-2021-jan-08_en&pk_campaign=rtd_news
- ʻO ka hoʻāʻo maʻi maʻi NCT02735707: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) Loaʻa ma ka pūnaewele ma https://clinicaltrials.gov/ct2/show/NCT02735707?term=NCT02735707&cond=Covid19&draw=2&rank=1#contacts
***
Comments ua paa.